Orkambi and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Orkambi (ivacaftor; lumacaftor), especially for people who are male, 30-39 old, have been taking the drug for 1 - 6 months also take Creon, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Weakness when taking Orkambi. It is created by eHealthMe based on reports of 9,494 people who have side effects when taking Orkambi from the FDA, and is updated regularly.

What is Orkambi?

Orkambi has active ingredients of ivacaftor; lumacaftor. eHealthMe is studying from 9,496 Orkambi users. Check the latest studies of Orkambi.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,613 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 30, 2026

9,494 people reported to have side effects when taking Orkambi.
Among them, 73 people (0.77%) have Weakness.

Among these 73 people:

How long have people been on Orkambi when they have Weakness? *

What is the gender of people who have Weakness when taking Orkambi? *

female: 43.66 %
male: 56.34 %

What is the age of people who have Weakness when taking Orkambi? *

What are other drugs people take besides Orkambi? *

What are other side effects people have besides Weakness? *

Dyspnea (difficult or laboured breathing): 34 people, 46.58%
Fatigue (feeling of tiredness): 33 people, 45.21%
Cough: 23 people, 31.51%
Nausea (feeling of having an urge to vomit): 21 people, 28.77%
Weight Decreased: 18 people, 24.66%
Fever: 17 people, 23.29%
Coughing Up Blood: 17 people, 23.29%
Diarrhea: 16 people, 21.92%
Pulmonary Function Test Decreased: 15 people, 20.55%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 15 people, 20.55%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 69 people, 94.52%
Wheezing (a high-pitched whistling sound made while you breath): 9 people, 12.33%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 9 people, 12.33%
Asthma: 9 people, 12.33%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 9 people, 12.33%
Blood Glucose Decreased: 9 people, 12.33%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 9 people, 12.33%
Cough: 9 people, 12.33%
Fungal Infection: 9 people, 12.33%
Sedation: 9 people, 12.33%

* Approximation only. Some reports may have incomplete information.

Do you take Orkambi and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Orkambi:

Orkambi (9,496 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Orkambi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,613 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ivacaftor; lumacaftor (the active ingredients of Orkambi) and Orkambi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.